The American company Moderna announced that its vaccine has proven 100% effective in the third phase of clinical trials.

According to Arabnet, the new results, which included more than 30,000 participants, showed that the vaccine is 100% effective in preventing severe risks of the Corona vaccine, by 94% In disease prevention on a larger scale.

the company says results are consistent across different demographics, including age, gender and ethnicity.

the company said that no serious safety concerns have been identified, with side effects limited to injection site pain, headache and fatigue.

Our company stated that, after collecting the required safety data for two months, it will apply for emergency use permission from the US Food and Drug Administration, in addition to obtaining a conditional marketing license From the European Medicines Agency.

the company says it has been informed that the FDA will meet to consider the vaccine on December 17th.

and Moderna expects to prepare 20 million doses to be shipped to the United States by the end of 2020, a number sufficient to immunize 10 million people because the vaccine requires two doses. The company says it is on track to manufacture between 500 million and 1 billion doses globally in 2021.

Speaking of the results, CEO Stefan Bansel emphasized the vaccine’s high success rate and, in particular, its ability to prevent severe disease. “We believe that our vaccine will provide a powerful new tool that may change the course of this epidemic and help prevent severe disease, hospitalization and death rates,” said Bansel.

And our Monday announcement is important for a number of reasons. Above all, it is another proven vaccine moving towards obtaining permission that will help tackle the Corona pandemic that has infected and killed millions of people around the world. In this way, the vaccine is more promising than the candidate vaccine from Pfizer and Biontech, which has also been submitted for regulatory approval after results from promising trials, as it requires less stressful storage requirements.

For science, this is also an important milestone, with RNA technology that has yet to hit the market (the Pfizer and Biontech vaccine was also manufactured with RNA). < / p>

This is also a huge achievement for Moderna, if the vaccine is approved, as no company has yet brought a vaccine to the market.